Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indian pharma industry...

    Indian pharma industry may achieve double-digit growth by 2030 via regulatory support from Government, says pharma industry body

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 15 Aug 2019 3:55 AM  |  Updated On 15 Aug 2019 3:55 AM
    Indian pharma industry may achieve double-digit growth by 2030 via regulatory support from Government, says pharma industry body

    "Ayushman Bharat Scheme that brings 40 per cent of the poor population under state-funded insurance cover also broadens possibilities to all healthcare ecosystem players including pharmaceutical companies," Secretary-General of Indian Pharmaceutical Alliance, Sudarshan Jain said.


    Ahmedabad: Indian pharmaceutical industry can achieve a target of double-digit growth by 2030 through a host of measures including regulatory support from the government like an increase in budgetary allocations for healthcare and promotion of innovation, a pharmaceutical industry body said.


    Setting a coherent pricing policy framework, simplifying regulatory approval processes, creating a separate Ministry of Pharmaceuticals and dedicated zones for the creation of medicines, are some of the ways that the government could help the industry achieve the ambitious target of becoming a USD 120-130 billion industry by 2030, it said.


    "We are seeking from government stable pricing policy. Whatever government decides in terms of drug pricing should be kept stable for at least five years, Secretary-General of Indian Pharmaceutical Alliance, Sudarshan Jain said here.


    The government should also aim to increase expenditure on healthcare from about 1.2 per cent to 2.5 per cent of GDP in the next five years, and to 5 per cent by 2030, for the industry to grow, Jain said.


    "Ayushman Bharat Scheme that brings 40 per cent of the poor population under state-funded insurance cover also broadens possibilities to all healthcare ecosystem players including pharmaceutical companies," he said.


    As per a report prepared by the IPA, at its current rate of 7-8 per cent CAGR, the Indian pharmaceutical industry is expected to grow about USD 80 to 90 billion by 2030.


    With a double-digit growth of 11-12 per cent, the industry can grow about USD 65 billion by 2024 and about USD 120 to 130 billion by 2030.


    Increased accessibility and affordability of healthcare, potential breakthroughs in next-generation innovative products, strong growth in the US market, and increased growth in large underpenetrated markets such as Japan and China are some of the ways for the industry to grow, Jain added.


    The industry body has also raised the demand for reducing GST on all drugs to a uniform 5 per cent, he said.


    Zydus Cadila CMD Pankaj Patel, a member company of the Alliance, said that innovation remains the focus for the future, and IPA is working in the direction of strengthening the innovation ecosystem in the Indian pharma industry.


    "The future is innovation, and IPA has taken innovation as a theme. It is working on innovation, in terms of collaboration between government institutions, industry, and making innovation go to the next level for the Indian pharma industry to grow. India has the capacity to develop drugs and sell it to the world," he said.


    Read Also: Indian pharma industry to grow at 11-13 per cent in FY2020, says rating agency Icra

    Ayushman Bharat schemeCAGRdouble growthHealthcareindian pharma industryIPAPankaj Patelpharmapharma companypharma newspharma news indiaPharmaceutical industrySudarshan JainZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok